Teva puts GSK and Amarin on notice with generic Lovaza launch

Lovaza--Courtesy of GlaxoSmithKline

Watch out, GlaxoSmithKline--and Amarin. Teva Pharmaceutical Industries ($TEVA) has launched its generic version of Glaxo's ($GSK) fish-oil pill, Lovaza, designed to lower triglyceride levels in patients with cardiovascular disease. Lovaza delivers $1.1 billion in U.S. sales for Glaxo annually, Teva says. But GSK isn't the only company likely to suffer from Teva's generic. Amarin's ($AMRN) rival product Vascepa will have to face the competition, too. Report